RxDoctor Payments Data

Larry Olinde, MD

Nephrology · West Monroe, LANPI 1720074453

Payments from drug & device makers

$4,002in general payments, 2019–2025

Across 202 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Bayer$759
  • Fresenius USA Marketing, Inc.$439
  • Akebia Therapeutics Inc$379
  • OPKO Pharmaceuticals, LLC$330
  • Amgen$227
  • plus $789 from 13 others

What the payments were for

  • Food & beverage$3,79395%
  • Education$2095%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,002 in reported general payments places this provider in the 60th percentile of 206 nephrology providers in Louisiana.

See all nephrology providers in Louisiana

Medicare billing

Part B allowed, 2024
$132,404
Medicare patients
264
Services billed
997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol308$216,574
VelphoroSucroferric Oxyhydroxide27$97,542
JardianceEmpagliflozin58$56,326
AuryxiaFerric Citrate16$49,323
KerendiaFinerenone38$34,648
RayaldeeCalcifediol29$34,116
VeltassaPatiromer Calcium Sorbitex19$19,192
LokelmaSodium Zirconium Cyclosilicate21$14,177
Doxazosin Mesylate138$3,009
Sevelamer Carbonate24$2,895
Nifedipine ErNifedipine83$2,384
Clonidine14$1,595
Potassium Chloride56$943
Losartan Potassium97$801
Amlodipine Besylate82$584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,078$230,751329 claims
Fresenius USA Marketing, Inc.Velphoro$439$97,54227 claims
Akebia Therapeutics IncAuryxia$379$49,32316 claims
BayerKerendia$759$34,64838 claims
OPKO Pharmaceuticals, LLCRayaldee$330$34,11629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 206 nephrology providers in Louisiana.

Other nephrology in West Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →